Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
3.210
-0.010 (-0.31%)
Apr 6, 2026, 1:31 PM EDT - Market open
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
10.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 500.00K | - | - |
| Dec 31, 2021 | 500.00K | - | - |
| Dec 31, 2020 | 500.00K | - | - |
| Dec 31, 2019 | 500.00K | - | - |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | 500.00K | - | - |
| Dec 31, 2016 | 500.00K | - | - |
| Dec 31, 2015 | 500.00K | - | - |
| Dec 31, 2014 | 500.00K | - | - |
| Dec 31, 2013 | 500.00K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 2.00M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 2.50M | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIMNN News
- 6 days ago - IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study - GlobeNewsWire
- 12 days ago - IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer - GlobeNewsWire
- 13 days ago - IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - GlobeNewsWire
- 2 months ago - IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY - GlobeNewsWire
- 3 months ago - IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 3 months ago - IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 - GlobeNewsWire
- 5 months ago - IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer - GlobeNewsWire